Janssen reports positive outcome from Voyage I trial of guselkumab to treat plaque psoriasis

Johnson& Johnson ’s Janssen Research& Development has reported a positive outcome from the first of the three pivotal Phase III Voyage I studies of guselkumab compared with adalimumab to treat adults with moderate-to-severe plaque psoriasis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news